Drug Trial Radar · NCT07632898
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
484
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
Jun 30, 2030
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Inhibikase TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label extension (OLE), single-arm study designed to assess the long-term safety and tolerability of oral IKT-001 administered once daily.
Conditions
- Pulmonary Arterial Hypertension (PAH)
Interventions
IKT-001Drug
IKT-001 tablets for PO administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs of special interestTime frame: From baseline to end of study (up to 2 years or availability of commercial product)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.